ArQule to Report Third Quarter 2014 Financial Results on November 10, 2014

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2014 on Monday, November 10, 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.

A replay of the conference call will be available beginning two hours after the completion of the call until the end of November 12, 2014 and can be accessed by dialing toll-free 855-859-2056 or 800-585-8367, and from outside the U.S. 404-537-3406. The confirmation code for replayed calls is 15276449.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family. ArQule’s current discovery efforts are focused on the identification of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.